Compare Eos Energy Enterprises Inc (EOSE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Natera Inc. Common Stock — how do they compare? Eos Energy Enterprises Inc trades at $1.94 (market cap $846.69M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 67.4× Eos Energy Enterprises Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 17 Days and Natera Inc. Common Stock for 0 Days on average.
| EOSE | NTRA | |
|---|---|---|
Market Cap | $846.69M | $57.03B |
Volume | 19,531,326 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $19.19 | $425.64 |
52-Week Low | $1.95 | $179.42 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $1.18B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.32, down 2.93% today, with bearish technical signals from moving averages despite oversold RSI readings. The company shows explosive revenue growth (from $114M in 2025 to $214M in 2026) but remains deeply unprofitable with negative gross margins and net losses. Recent catalysts include a $87M DOE loan advance and a Google partnership for a West Virginia energy project, driving positive media coverage.
The stock presents high-risk speculation with Wall Street analysts maintaining a cautious 'Hold' consensus (63.64%) despite a $7.10 price target implying 206% upside. Investment appeal hinges on EOSE scaling production and achieving profitability, but substantial execution risks and cash burn require careful monitoring. Current valuation at 4.46x sales appears stretched given persistent losses.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
